Human TNF RI/TNFRSF1A Quantikine ELISA Kit

Product Details

Reactivity HuSpecies Glossary
Applications ELISA

Order Details

View Available Conjugates
Catalog# & Conjugate Size Price

Human TNF RI/TNFRSF1A Quantikine ELISA Kit Summary

The Quantikine Human sTNF RI Immunoassay is a 4.5 hour solid phase ELISA designed to measure sTNF RI in cell culture supernates, serum, plasma, and urine. It contains E. coli-expressed recombinant human sTNF RI, as well as antibodies raised against this polypeptide. The recombinant protein represents the non-glycosylated, N-terminal methionyl form of the naturally occurring human so...luble Type I receptor for TNF with an apparent molecular weight of approximately 18.6 kDa. This immunoassay has been shown to accurately quantitate the recombinant sTNF RI. Results obtained on samples containing natural sTNF RI showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values of natural sTNF RI. Since the measurement of human sTNF RI by this immunoassay is relatively insensitive to added TNF-alpha or TNF-beta, it is probable that this measurement corresponds to the total amount of the soluble receptor present in samples (i.e. the total amount of free receptor plus the total amount of receptor bound to TNF).
Show More
Natural and recombinant human sTNF RI
Assay Type
Solid Phase Sandwich ELISA
See PDF Datasheet for details
See PDF Datasheet for details
Spike Recovery
See PDF Datasheet for details
Sample Volume
See PDF Datasheet for details


Application Notes
Interference observed with 1 or more available related molecules.
Read Publications using DRT100.

Packaging, Storage & Formulations

Store the unopened product at 2 - 8 °C. Do not use past expiration date.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human TNF RI/TNFRSF1A Quantikine ELISA Kit

  • CD120a antigen
  • CD120a
  • FPF
  • p55
  • p55-R
  • p60
  • TNF RI
  • TNFARMGC19588
  • TNF-R
  • TNF-R1
  • TNFR55
  • TNF-R55
  • TNFR60
  • TNF-RI
  • TNF-R-I
  • TNFR-I
  • tumor necrosis factor binding protein 1
  • Tumor necrosis factor receptor 1
  • tumor necrosis factor receptor 1A isoform beta
  • tumor necrosis factor receptor superfamily member 1A
  • tumor necrosis factor receptor superfamily, member 1A
  • tumor necrosis factor receptor type 1
  • Tumor necrosis factor receptor type I
  • tumor necrosis factor-alpha receptor


Tumor necrosis factors (TNFs) are pleiotropic cytokines that are considered primary modifiers of the inflammatory and immune reactions of animals produced in response to injury or infection. Two forms of TNF, designated TNF-alpha (or cachectin) and TNF-beta (or lymphotoxin), have been described that share 30% sequence similarity and compete for binding to the same receptors. TNFs play a necessary and beneficial role as mediators of host resistance to infections and tumor formation. However, over-production or inappropriate expression of these factors can lead to a variety of pathological conditions, including wasting, systemic toxicity, and septic shock. For reviews of the literature relating to these factors, see references 1 and 2. 
The actions of TNFs are produced subsequent to binding of the factors to cell surface receptors. Two distinct TNF receptors have been identified and cloned. Virtually all cell types studied show the presence of one or both of these receptor types. One receptor type, termed TNF RII (Type A, Type a, 75 kDa or utr antigen), shows an apparent molecular weight of 75 kDa. The gene for this receptor encodes a presumptive transmembrane protein of 439 amino acid (aa) residues (3, 19). The other receptor type, termed TNF RI (Type B, Type b, 55 kDa or htr antigen), shows an apparent molecular weight of 55 kDa. The gene for this protein encodes a transmembrane protein of 426 aa residues (4, 5, 19). Both receptor types show high affinity binding of either TNF-alpha or TNF-beta . The two receptor types are immunologically distinct but their extracellular domains show similarities in the pattern of cysteine residue locations in four domains (3). The intracellular domains of the two receptor types are apparently unrelated, suggesting the possibility that the two receptor types employ different signal transduction pathways. 
Several groups have identified soluble TNF binding proteins in human serum and urine (6-8) that can neutralize the biological activities of TNF-alpha and TNF-beta . Two types have been identified and designated sTNF RI (or TNF BPI) and sTNF RII (or TNF BPII). These soluble forms have now been shown to represent truncated forms of the two types of TNF receptors discussed above. The soluble receptor forms apparently arise as a result of shedding of the extracellular domains of the receptors, and concentrations of about 1-2 ng/mL are found in the serum and urine of healthy subjects (9, 10). The levels of the soluble receptors vary from individual to individual but are stable over time for given individuals (9). 
Elevated levels of TNF receptors have been found in the amniotic fluid and urine of pregnant women (11), in serum or plasma in association with pathological conditions such as endotoxinemia (12, 13), meningiococcemia (14), and HIV infection (15), and in plasma and ascites of patients in association with infections and malignancies (16). The mechanisms involved in the induction of shedding of the TNF receptors are not well understood. There are reports of correlations between increased TNF levels and soluble receptor levels, suggesting generally that stimuli that cause TNF levels to rise also induce shedding of TNF receptors (12-14, 17). There is also evidence, however, that suggests the shedding of the two types of soluble receptors is independently regulated (13). 2 For research use only. Not for use in diagnostic procedures. 
The physiological role of the soluble TNF receptors is not known. It is known that both types of soluble receptors can bind to TNF in vitro and inhibit its biological activity by competing with cell surface receptors for TNF binding. Consequently it has been suggested that shedding of soluble receptors in response to TNF release could serve as a mechanism for binding and inhibiting the TNF not immediately bound to surface receptors, thus protecting other cells from the effects of TNF and localizing the inflammatory response (12, 17). It is also possible that shedding of receptors represents a mechanism for desensitizing the cells that shed the receptors from the effects of TNF (17). On the other hand, it has been reported that at low concentrations of TNF, binding to soluble receptors can stabilize TNF and augment some of its activities (18). Thus it is possible that under some conditions the pool of TNF bound to soluble receptors could represent a reservoir for the stabilization and controlled release of TNF

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: ELISA
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu
Applications: BA
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-Fr, IHC-P, MiAr, WB
Species: Hu
Applications: CyTOF-ready, Flow, IHC, Neut
Species: Hu
Applications: ICC, WB
Species: Hu
Applications: ELISA, IHC, IHC-P, KD, PLA, S-ELISA, WB
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-Fr, IHC-P, IP, Simple Western, WB
Species: Hu
Applications: CyTOF-ready, Flow, IHC, Neut, WB
Species: Hu
Applications: ELISA
Species: Hu, Rb, Rt
Applications: Flow, IHC, IHC-P, KO, WB
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, WB
Species: Mu
Applications: ELISA
Species: Hu
Applications: Flow, ICC/IF, IHC, IHC-P, IP, WB
Species: Hu
Applications: BA
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to

Publications for TNF RI/TNFRSF1A (DRT100)(82)

We have publications tested in 6 confirmed species: Human, Mouse, Primate - Cholrocebus pygerythrus (Vervet Monkey), Primate - Macaca mulatta (Rhesus Macaque), Primate - Papio cynocephalus (Yellow Baboon), Primate - Papio hamadryas (Hamadyras Baboon).

Filter By Application
All Applications
Filter By Species
Primate - Cholrocebus pygerythrus (Vervet Monkey)
Primate - Macaca mulatta (Rhesus Macaque)
Primate - Papio cynocephalus (Yellow Baboon)
Primate - Papio hamadryas (Hamadyras Baboon)
All Species
Showing Publications 1 - 10 of 82. Show All 82 Publications.
Publications using DRT100 Applications Species
KHT Salai, LY Wu, JR Chong, YL Chai, B Gyanwali, C Robert, S Hilal, N Venketasub, GS Dawe, CP Chen, MKP Lai Elevated Soluble TNF-Receptor 1 in the Serum of Predementia Subjects with Cerebral Small Vessel Disease Biomolecules, 2023-03-13;13(3):. 2023-03-13 [PMID: 36979460] (Human) Human
T Gohda, M Murakoshi, Y Suzuki, M Hiki, T Naito, K Takahashi, Y Tabe Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients PLoS ONE, 2022-10-11;17(10):e0275745. 2022-10-11 [PMID: 36219652] (Human) Human
T Hinton, D Karnak, M Tang, R Jiang, Y Luo, P Boonstra, Y Sun, DJ Nancarrow, E Sandford, P Ray, C Maurino, M Matuszak, MJ Schipper, MD Green, GA Yanik, M Tewari, IE Naqa, CA Schonewolf, RT Haken, S Jolly, TS Lawrence, D Ray Improved prediction of radiation pneumonitis by combining biological and radiobiological parameters using a data-driven Bayesian network analysis Translational Oncology, 2022-04-20;21(0):101428. 2022-04-20 [PMID: 35460942] (Human) Human
Z Albar, M Albakri, J Hajjari, M Karnib, SE Janus, SG Al-Kindi Inflammatory Markers and Risk of Heart Failure With Reduced to Preserved Ejection Fraction The American journal of cardiology, 2022-01-03;0(0):. 2022-01-03 [PMID: 34986991] (Human) Human
T Takao, H Yanagisawa, M Suka, Y Yoshida, Y Onishi, T Tahara, T Kikuchi, A Kushiyama, M Anai, K Takahashi, S Wakabayash, H Yamazaki, S Kawazu, Y Iwamoto, M Noda, M Kasuga Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes: The Asahi Diabetes Complications Study Journal of diabetes investigation, 2021-10-07;0(0):. 2021-10-07 [PMID: 34533892] (Human) Human
A Wardzy?ska, M Pawe?czyk, J Rywaniak, J Makowska, J Jamroz-Brz, ML Kowalski Circulating miRNA expression in asthmatics is age-related and associated with clinical asthma parameters, respiratory function and systemic inflammation Respiratory Research, 2021-06-10;22(1):177. 2021-06-10 [PMID: 34112152] (Human) Human
M Oshima, A Hara, T Toyama, M Jun, C Pollock, M Jardine, S Harrap, N Poulter, ME Cooper, M Woodward, J Chalmers, V Perkovic, MG Wong, T Wada Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor Kidney international reports, 2020-11-10;6(2):284-295. 2020-11-10 [PMID: 33615053] (Human) Human
MM Cousins, E Morris, C Maurino, TP Devasia, D Karnak, D Ray, ND Parikh, D Owen, RK Ten Haken, MJ Schipper, TS Lawrence, KC Cuneo TNFR1 and the TNF&alpha axis as a targetable mediator of liver injury from stereotactic body radiation therapy Translational Oncology, 2020-12-13;14(1):100950. 2020-12-13 [PMID: 33395747] (Human) Human
R Cezar, A Winter, D Desigaud, M Pastore, L Kundura, AM Dupuy, C Cognot, T Vincent, C Reynes, C Dunyach-Re, JP Lavigne, R Sabatier, P Le Merre, E Maggia, P Corbeau Identification of distinct immune activation profiles in adult humans Scientific Reports, 2020-11-30;10(1):20824. 2020-11-30 [PMID: 33257766] (Human) Human
L Hassan, D Medenwald, D Tiller, A Kluttig, B Ludwig-Kra, FB Kraus, KH Greiser, R Mikolajczy The association between change of soluble tumor necrosis factor receptor R1 (sTNF-R1) measurements and cardiovascular and all-cause mortality-Results from the population-based (Cardiovascular Disease, Living and Ageing in Halle) CARLA study 2002-2016 PLoS ONE, 2020-10-26;15(10):e0241213. 2020-10-26 [PMID: 33104754] (Human) Human
Show All 82 Publications.

Reviews for TNF RI/TNFRSF1A (DRT100) (0)

There are no reviews for TNF RI/TNFRSF1A (DRT100). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

Product General Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for TNF RI/TNFRSF1A (DRT100) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional TNF RI/TNFRSF1A Products

Bioinformatics Tool for TNF RI/TNFRSF1A (DRT100)

Discover related pathways, diseases and genes to TNF RI/TNFRSF1A (DRT100). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for TNF RI/TNFRSF1A (DRT100)

Discover more about diseases related to TNF RI/TNFRSF1A (DRT100).

Pathways for TNF RI/TNFRSF1A (DRT100)

View related products by pathway.


Learn more about PTMs related to TNF RI/TNFRSF1A (DRT100).


There are no specific blogs for TNF RI/TNFRSF1A, but you can read our latest blog posts.

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Review this Product

Be the first to review our Human TNF RI/TNFRSF1A Quantikine ELISA Kit and receive a gift card or discount.


Gene Symbol TNFRSF1A